Relapse Clinical Trials in Houston, Texas
37 recruitingHouston, Texas
Showing 1–20 of 37 trials
Recruiting
Phase 1Phase 2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled18 locationsNCT04989803
Recruiting
Phase 1Phase 2
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Relapsed/RefractoryB-cell Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06287229
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1Phase 2
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Relapsed Small Cell Lung CancerRecurrent Small Cell Lung Cancer
VA Office of Research and Development166 enrolled11 locationsNCT06681220
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 1
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.70 enrolled8 locationsNCT02926690
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Refractory Acute LeukemiaPediatric Relapsed
M.D. Anderson Cancer Center22 enrolled1 locationNCT06397027
Recruiting
Phase 1Phase 2
A Study of Revumenib and Mezigdomide in People With Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Memorial Sloan Kettering Cancer Center52 enrolled10 locationsNCT07356154
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled14 locationsNCT06714591
Recruiting
Phase 1
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences124 enrolled7 locationsNCT06549790
Recruiting
Phase 1
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Hemogenyx Pharmaceuticals LLC18 enrolled1 locationNCT06786533
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia, in Relapse
Bio-Path Holdings, Inc.48 enrolled4 locationsNCT05190471
Recruiting
Phase 1
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Relapsed Adult AML
Pacylex Pharmaceuticals35 enrolled1 locationNCT06613217